Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB14 vs Pembrolizumab in First-Line NSCLC (TPS ≥10%)
NCT07362459Phase 3Recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SCTB14 in non-small cell lung carcinoma (NSCLC), sponsored by Sinocelltech Group Limited. Started Dec 2025; status: recruiting.
02
Drugs
SCTB14
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT07362459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362459.